Ocugen Doses First Patient in the ArMaDa Clinical Trial
Ocugen, Inc. has just initiated the ArMaDa Phase 1/2 clinical trial for OCU410 (AAV-RORA), a gene therapy product for dry age-related macular degeneration (dAMD).
The trial's first patient has been dosed successfully, marking a significant milestone in vision restoration research. GA, a severe form of dAMD, affects millions globally, underscoring the need for novel treatments like OCU410. OCU410 utilizes an AAV delivery platform for retinal delivery of the RORA gene, addressing lipid metabolism, oxidative stress, and inflammation pathways associated with dAMD.
“I am excited that we performed the first surgery with this novel therapeutic approach—designed to restore homeostasis and slow disease progression following a single treatment—at ARC in Phoenix, AZ, with the surgical team led by Dr. Mark Kwong, medical director of ARC.” said Benjamin Bakall, MD, PhD, PI in collaboration with DocTrials.